ABVC Provides Oncology Pipeline Updates

2 years ago

Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via…

Better Choice Company Announces Halo Holistic Pet Food’s Improved Formulation and Brand Overhaul

2 years ago

Features High-Quality Ingredients and Complete Digestive HealthNEW YORK, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR), a…

Medical Device Association Launches Hub for Research, Standards, News: AAMI ARRAY

2 years ago

ARLINGTON, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation (AAMI) has launched a…

CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Cardiology 2022 Congress

2 years ago

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present…

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

2 years ago

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the…

LifeMD and Cleared Offer New Hope to Allergy Patients Through Strategic Partnership With Allergenis

2 years ago

Strategic partnership enables direct-to-consumer food allergy clinic to provide convenient access to crucial peanut allergy threshold informationNEW YORK, Aug. 22,…

Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain

2 years ago

MALVERN, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute…

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.

2 years ago

LBS-008 (aka Tinlarebant) is Belite Bio’s orally administered tablet for the treatment of Stargardt disease (STGD1) and Dry AMDA 2-year…

Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update

2 years ago

Dosed first patient in Phase I/II trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid…

Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) – expressing cancers

2 years ago

BOSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class…